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There has been a general increase in psychiatric symptoms since the COVID-19 
pandemic began. Literature that has been published since the start of the pandemic has 
indicated there is an increased risk of depression, insomnia, altered mental status, new-
onset psychosis, neurocognitive syndrome, and anxiety. The military veteran population 
is at higher risk for psychiatric illness than the general population, and should be 
screened accordingly. This quality improvement project was developed in collaboration 
with the mental health clinic at urban medical center in the Midwest to identify new 
symptoms of mental illness after COVID-19 diagnosis utilizing the PDSA model and 
descriptive statistics. Veterans were screened via telephone for depression, anxiety, 
psychosis, PTSD, and dementia utilizing the PHQ-9, GAD- 7, PCCL, PCL-5 and TMMS. 
A 6% positivity rate for symptoms of new onset mental illness was found in a sample size 




Identification of Veterans Experiencing Symptoms of Mental Illness for the First 
Time After COVID-19 Diagnosis 
There has been a general increase in psychiatric symptoms since the COVID-19 
pandemic began, and a high number of veterans at an urban Midwest medical center have 
been diagnosed with COVID-19. This increase in psychiatric exacerbation falls on 
several different spectrums of mental illness. Guo et al. (2020) found that direct exposure 
to COVID-19 increased the risk for depression and insomnia. In a UK-wide surveillance 
study that focused specifically on neurological and psychiatric complications of COVID-
19, altered mental status, new-onset psychosis, neurocognitive syndrome, and affective 
disorders were identified (Varatharaj et al, 2020). Significant anxiety associated with the 
pandemic and a positive diagnosis has led to the creation of a coronavirus-specific 
anxiety scale (Lee, 2020), while case studies of new-onset psychosis while being treated 
for coronavirus have been published (Boulos et al., 2020). Stigma associated with a 
positive diagnosis is also affecting mental health; Gunnell et al. (2020) stress the 
importance of suicide prevention during the pandemic. Brooks et al. (2020) completed a 
literature review that highlighted the long-lasting psychological impact of quarantine.  
These symptoms indicate a need to identify high-risk groups and intervene when 
possible. Studies completed in China after the initial outbreak suggest that identification 
of high-risk groups for early psychological intervention can have a positive effect (Wang 
et al., 2020) and past epidemics have demonstrated that mental health sequelae can have a 
longer lasting impact (Ornell et al., 2020). Increased screening has been shown to 
improve access to care for patients with mental illness (Lamontagne-Godwin et al., 2018 
& Webb et al., 2016). Additionally, health care advocates have the ability to influence 
 
 
vulnerable individuals and identify the right type of health care (Thomas et al, 2019). 
 The military veteran population is at higher risk for psychiatric illness (25%) than 
the general population (20.6%) (Kessler et al., 2014 & National Institute of Mental 
Health, 2021), and at the time of this study, there were over 1500 veterans at the medical 
center who have tested positive for COVID-19. The purpose of this project is to identify 
veterans experiencing symptoms of psychiatric illness for the first time after COVID-19 
diagnosis and refer them to mental health services. The Plan-Do-Study-Act model will be 
utilized to guide this project. Outcomes to assess include the number of COVID-19 
positive veterans with no past psychiatric history who have significant symptoms of 
mental illness, the number of COVID-19 positive veterans who require a mental health 
referral after screening for psychiatric symptoms, and the number of veterans who 
received mental health care after referral at 3 months, including medication management 
and psychotherapy at the medical center or in the community setting. The goal is to 
improve care for an already high-risk patient population. 
Review of Literature 
 A literature review (Appendix A) was conducted in July 2020 utilizing the 
Summon, PsychINFO and CINAHL databases from the last 5 years. Initial terms 
included “COVID-19” and “mental health.” This identified more than 107,000 articles. 
The search was further refined to “symptoms,” “coronavirus,” “SARS-COV-2” and 
“COVID-19 diagnosis.” This search yielded seventeen articles that met inclusion criteria. 
Articles were considered for inclusion if they addressed symptoms of mental illness in 
the adult population and their symptom response to COVID-19. Articles were excluded if 
they only assessed the adolescent population or if they did not identify symptoms present 
 
 
with a positive COVID-19 diagnosis. Limitations of this initial search include most 
research has been conducted in Asia and Europe.  
 The increase in neuropsychiatric symptoms after a positive COVID-19 diagnosis 
has been described in the literature. Reports suggest that the novel coronavirus is similar 
to the SARS-CoV-1 virus in its ability to invade neurons causing delirium, psychosis, and 
persistent cognitive problems (Riordan, 2020). This similarity may also affect long-term 
vulnerability to neuropsychiatric effects (Riordan, 2020), including biological aspects, 
which may increase vulnerability to PTSD (Horesha & Brown, 2020). Most recently, it 
has been found that a COVID-19 diagnosis was associated with increase in psychiatric 
illness in the following 14- 90 days (Taquet et al., 2020). 
In Chinese adults with direct exposure to COVID-19, there was an increase in 
depression and insomnia (Guo et al., 2020). In the United Kingdom, one in five people 
with a positive COVID-19 diagnosis developed neuropsychiatric complications 
(Varatharaj et al., 2020). These included new-onset psychosis, neurocognitive syndrome, 
and mood affective disorders, in both younger and older populations (Varatharaj et al., 
2020). Two case studies from the United States and United Kingdom also describes new-
onset psychosis and delusions after COVID-19 diagnosis (Boulos et al., 2020 & Smith et 
al., 2020). Another case study in China identified manic-like symptoms for the first time 
after COVID-19 diagnosis (Lu et al., 2020). High levels of anxiety have also been found 
in patients with COVID-19, to the extent that a Coronavirus Anxiety Scale has been 
developed to assess for this (Lee, 2020). Gruber et al. (2020) found an increase in 
anxiety, depression, acute stress disorder, PTSD, and substance use disorders. These 
 
 
symptoms may also increase the risk of suicide, and measures should be taken to address 
this (Gunnell et al., 2020). 
 Several studies suggest that identification of high-risk groups is necessary. In an 
initial study published in February 2020, Wang et al., stress the importance of identifying 
high-risk groups with the goal of earlier psychological intervention. Ornell et al. (2020) 
echo this, stating that multidisciplinary mental health teams should be included to 
develop these strategies to establish safe psychological counseling services. In a 
longitudinal study conducted in Spain by Gonzalez-Sanguino et al. (2020), the need to 
identify vulnerable groups over the course of the pandemic was identified. Lamontagne-
Goodwin, et al., (2018) and Webb et al., (2016) found that an increase in screening 
increased access to mental health services in people with mental illness and improved 
outcomes. In addition, it has been found that ‘health service brokers’ or advocates are 
able to identify vulnerable patients and link them to appropriate health care services 
(Thomas et al., 2019). It has also been documented that Black Americans experience 
higher COVID-19 rates, and PTSD rates are already higher among Black Americans 
(Novacek et al., 2020). Novacek et al. (2020) recommend early identification and 
treatment for PTSD for this patient population.  
 The psychological impact of quarantine has also been discussed in the literature. 
The term “pandemic fear” has been used in the past during epidemics when talking about 
the mental health side effects. Ornell et al. (2020) and Gruber et al. (2020) refer to the 
defense mechanisms fear and anger during life-threatening events, the ensuing allostatic 
load, and how this can contribute to the development of various psychiatric disorders in 
chronic states. In the first few weeks following the outbreak in China, more than half of 
 
 
the participants in one study reported the psychological impact of the pandemic and 
ensuing quarantine as moderate-to-severe (Wang et al., 2020). Brooks et al. (2020) 
conducted a literature review and further identified the following stressors related to 
quarantine: long duration, fear of infecting others, frustration, boredom, inadequate 
information, financial concerns, and stigma. 
 The Plan-Do-Study-Act (PDSA) model was selected to guide this project for its 
focus on quality improvement (Scoville & Little, 2014). By breaking down the steps into 
plan, do, study, and act, this model breaks down the thinking process into steps so that the 
outcome can be evaluated, improved, and tested again (Scoville & Little, 2014). The 
planning stage involved meeting with the members of the mental health clinic to 
determine the scope of the project.  
 The increase in neuropsychiatric symptoms after COVID-19 is being established 
in the literature. The long-term impact of these symptoms has yet to be seen. These 
symptoms range from mood, anxiety, psychosis, and PTSD, all which could also lead to 
suicidal behaviors. The impact of quarantine after diagnosis is also significant, and may 
contribute to these symptoms. Veterans already have an increased incidence of mental 
illness, and are a vulnerable population. Screening veterans without a history of mental 
illness may improve access to care and improve health outcomes long-term.  
Method 
Design 
This project was initially identified by the clinic lead in the mental health clinic at 
the medical center after reading early reports of people developing symptoms of mental 
illness after COVID-19 diagnosis. Preliminary conversations with stakeholders within the 
mental health clinic established the need for further evaluation of this patient population. 
 
 
There is no current process to further assesses veterans for symptoms of mental illness 
after COVID-19 diagnosis. A study design was created with the assistance of the medical 
center liaison for this project. 
This quality improvement project was conducted utilizing a cohort design 
following the PDSA model. A retrospective chart query was conducted to identify 
patients with a positive COVID-19 diagnosis without a documented history of mental 
illness. Data was queried from March 2020 to March 2021. The initial interview was 
conducted by phone and included the veteran self-reporting responses to questions within 
the screening tools. The 30 day follow up was conducted via chart review. 
Setting 
This project took place in the Midwest, at an urban medical center with two 
campuses. This medical center provides inpatient and ambulatory care in a two-division 
facility for veterans living in the Midwest and surrounding areas (U.S. Department of 
Veterans Affairs, 2015). To be eligible for services at this medical center, a veteran must 
provide proof of service, usually an Armed Forces Report of Transfer or Discharge (U.S. 
Department of Veterans Affairs, 2015).  
Sample 
This purposeful sample was veterans with a positive COVID-19 diagnosis in the 
project’s medical center. Veterans were identified utilizing a retrospective chart review 
with the electronic medical record. Inclusion criteria was no documented history of 
mental illness, male or female, ages 18 through 89, and receiving health care services at 
the medical center. Exclusion criteria was age < 18 or > 89, a documented history of 
mental illness, including major depressive disorder, generalized anxiety disorder, panic 
 
 
disorder, adjustment disorder, post-traumatic stress disorder, schizophrenia, unspecified 
psychosis, bipolar I or II disorder, suicide attempts, schizoaffective disorder, or dementia 
in the electronic medical record. ICD-9 and ICD-10 codes were used to identify exclusion 
criteria (Appendix B). A second review of the veteran’s face sheet in the electronic 
medical record was completed to identify additional diagnoses. If no previous mental 
illness was documented, the veteran was then be screened for mental illness.  
Data Collection/Analysis 
Data that was collected and analyzed included the following (Appendix C): the 
number of COVID-19 positive veterans with no past psychiatric history who have 
significant symptoms of mental illness as indicated by the Patient Health Questionnaire 
(PHQ)-9, Generalized Anxiety Disorder Scale (GAD)-7, PTSD Check List (PCL)-5, The 
Early Detection Primary Care Check List (PCCL) and Mini Mental Status Exam (MMS); 
the number of COVID-19 positive veterans who require a mental health referral after 
screening for psychiatric symptoms; the number of veterans who received mental health 
care after referral at 30 days, including medication management and psychotherapy at the 
medical center; and the number of veterans who received mental health care after referral 
at 30 days, including medication management and psychotherapy in the community 
setting.  
The PHQ-9 is screening tool for depression intended for use in primary care. The 
PHQ-9 has nine questions that the patient answers using a Likert scale, with one 
additional question to be answered if one of the first nine questions was positive 
(Kroenke et al., 2001). A score of 10- 14 indicates mild depression. A score of 15- 19 
indicates moderately severe major depression, and a score greater than 20 indicates 
 
 
severe major depression (Kroenke et al., 2001). A cut-off score of 10 will be utilized for 
this project as this indicates mild depressive symptoms. In three recent studies, the PHQ-
9 performed well to identify symptoms of depression (α= .87) (Beard et al, 2015, Levis et 
al., 2019 & Manea et al., 2015).  
The GAD-7 is screening tool for anxiety utilized in primary care. The GAD-7 is a 
7-item self-report measure. Scores between 5-9 indicate mild anxiety, 10- 14 moderate 
anxiety, and scores greater than 15 severe anxiety (Spitzer et al., 2006). A cut-off score of 
10 will be used for this project. This tool was recently evaluated and found to be a 
psychometrically sound instrument (sensitivity 0.83 and specificity 0.84) to identify 
patients with anxiety disorders (Jordan et al., 2017 & Plummer et al., 2015).  
The PCCL is a 20-item tool that assesses general functioning, psychological and 
social contexts, hallucinations, delusions, and disorganized speech and thinking 
(Addington et al., 2015). This tool has demonstrated an 89% sensitivity and a 60% 
specificity (Addington et al., 2015). A screen would be considered positive if the score 
was 20 or greater or endorsement of any of the five key indicators (Addington et al., 2015 
& French et al., 2012). For this project, the same criteria will be utilized.  
The PCL-5 is a screening tool for PTSD for the civilian and military population. It 
is a 20-item self-report that assesses a person’s response to a distressing event over the 
past month (Weathers et al., 2013 & Wortman et al., 2016). In 2016, the PCL-5 was 
found to be psychometrically sound (α= .91) with high internal consistency (Wortman et 
al, 2016). PTSD should be considered when a person endorses a severity of at least two in 
each cluster (Wortman et al., 2016), and this will be the criteria for this project. 
 
 
The MMSE was originally designed as a 30-point in-person exam to measure 
cognitive impairment (Tariq et al., 2006). The maximum score is 30; a score of <24 is 
considered abnormal (Hunt et al., 2017). Due to the telehealth approach of this project, a 
literature review was conducted to determine the validity of administering this exam via 
telehealth. In a study by Ciemens et al. (2009), the traditional in-person MMSE was 
compared to telehealth delivered MMSE and was found to have a 90% correlation 
between the two delivery methods. Newkirk et al. (2004) corroborated this finding, 
demonstrating a .88 correlation. The adapted 23-point exam will be utilized for this 
project, with a score of <21 considered abnormal and prompting referral.  
Potential risks for veterans include loss of confidentiality and distress from the 
sensitive nature of the questions asked, with protections as outlined below. Benefits of 
participation include accessing the appropriate resources for mental health care. 
Participation in this quality improvement project took approximately 15 minutes of the 
veteran’s time.  
Participants’ data was securely saved in a password-protected folder, derived 
from chart information in previous admissions. Participants medical information was 
protected via a coded system and stored on a password protected limited-access medical 
center server. Identifiers were coded, and the coded list kept in a separate limited-access, 
password protected file (Appendix D). The linked code between data and identifiers will 
be kept for 6 years after the end of the fiscal year the study was completed or as long as 
bound by other federal requirements in compliance with RSC 10-1. Passwords for this 
file will maintain minimum standard requirements as endorsed by the medical center for 
strong passwords. Removal of access to study data will be performed for study personnel 
 
 
when they are no longer part of the research team. Descriptive statistics will be used for 
analysis.  
Approval Process 
The approval process began by determining if this was a QI/QA project through 
the medical center Research Office. The medical center ACOS determined this project 
was quality improvement. A further review of the project was conducted by the medical 
center institutional review board, and was determined to be a quality improvement 
project. This project was also reviewed by the university institutional review board and 
was acknowledged as a quality improvement project. 
Procedures  
A query report was utilized to identify veterans with a positive COVID-19 
diagnosis. At the time of this study, there were over 1500 veterans with a positive 
COVID-19 diagnosis. Once identified, a query report determined if the veteran has been 
previously diagnosed with a mental illness. Veterans were contacted in April 2021 until a 
sample size of 50 was reached.  
The veteran with no previous mental illness was then screened via telephone. 
Verbal consent (Appendix E) was obtained at the beginning of the conversation to alert 
the veteran that assessment questions contained sensitive information. The Doximity 
smartphone application was utilized to protect veteran and investigator privacy. The 
number was linked to the medical center liaison’s office phone number, where secure 
messages can be left. Three attempts were made to contact the veteran. After the first 
attempt, a voice mail message was left stating when the next call will be made or to 
return the phone call (Appendix F). If a return call was not received after one week, a 
 
 
second attempt was made. The same applied for the third phone call. If after three 
attempts to reach the veteran, contact was not made, then no additional attempts occurred.  
Initially, the veterans were screened for symptoms of depression and anxiety 
using the PHQ-9 and GAD-7. Further assessment for PTSD using the PCL-5 and 
psychosis using the PCCL was completed. To complete the screening, a MMSE was 
performed. Once the screening was completed and a positive value on any of the five 
tools was found, the veteran determined if he/she is amenable to a mental health clinic 
referral for further care (Figure 1). If so, the veteran was referred to the mental health 
clinic for further care and a referral was placed in the electronic medical record. If the 
veteran declined mental health referral, the number for the medical center crisis line was 
given to the veteran. If the PHQ-9 or PCL- 5 indicated suicidality during the assessment, 
a licensed independent practitioner at the mental health clinic was available to assess the 
veteran within 24 hours per the medical center standard operating procedure. The study 
team planned to collaborate with local Psychiatric Emergency Services and/ or the 
participant’s primary care provider to develop a treatment plan that adequately addresses 
the suicidal thoughts or behavior if identified. A note (Appendix G) was placed in the 
veteran’s electronic medical record that screening was completed, along with the results. 
The note was coded with diagnostic code Z13.9 (encounter for screening, unspecified) 
and procedure code 96127 (brief behavioral assessment). This note was co-signed by the 
medical center liaison for this project.  
Once the mental health clinic received the referral, an appointment was made for 
a full mental health intake assessment and initiation of an appropriate treatment plan. 
 
 
After 30 days, the medical record was reviewed to validate if a mental health clinical 
appointment had been made, and what treatment plan was initiated.  
Figure 1 









 When this project was conceived, there were approximately 300 veterans in the 
medical center with a positive COVID-19 diagnosis. At the time of project 
implementation, 1,513 veterans in the medical center had tested positive for COVID-19. 
From this data, 216 charts were reviewed utilizing a random number generator (Figure 2). 
In this initial chart review, 127 of the veterans were exclude because of a previous mental 
health diagnosis, representing 59% of the veterans in the randomized group selected for 
screening for inclusion in the project. 
Figure 2 




When contact was made, each phone call lasted between 10- 20 minutes, 
depending on veteran responses. Three veterans had positive screens, and two had mental 
health clinic referrals placed. One veteran declined the mental health clinic referral and 
the appropriate resources were provided to the patient. One patient was assessed by the 
mental health clinic and a treatment plan was implemented. This veteran opted for 
individual psychotherapy at the medical center, and deferred medication management. 
One veteran did not return the phone calls from the mental health clinic to schedule an 
appointment. This resulted in a 6% positivity rate for new symptoms of mental illness for 
this project.  
In this sample, 94% (47) of the veterans were male; 6% (3) veterans were female. 
The average age was 63.1 years (range 30- 88). The average time since COVID-19 
diagnosis was 140.48 days (range 51- 178). The average score of each instrument is 
shown in Table 1. The PHQ-9 assesses for depressive symptoms and a score of 10- 14 
indicates mild depression. The mean value of participants was 2.34 (range 0- 13). The 
GAD-7 assesses for anxiety; scores between 10- 14 indicate moderate anxiety. The mean 
value of participants was 1.76 (range 0- 15).  The PCCL is a tool used to assess for 
symptoms of psychosis; a score of 20 or greater is considered positive. The mean value of 
participants was 1.44 (range 0- 14). The PCL-5 is tool to assess for PTSD; the PCL-5 is 
considered positive when a person endorses a severity of 2 in each cluster. The mean 
value of participants was 1.44 (range 0- 14). There were no participants who endorsed a 
severity of 2 each cluster that met the criteria for PTSD. The MMSE was designed to 
measure cognitive impairment and for this project, the tele MMSE was utilized. The max 
 
 
score is 23; a score less than 21 was considered positive. The mean value for participants 













PHQ-9 10 3 2.34 3.05 0- 13 
GAD- 7 10 2 1.76 3.04 0- 15 
PCCL 20 0 1.44 3.15 0- 14 
PCL- 5 6 0 1.04 2.83 0-13 
TMMS 20 2 22.5 1.80 11-23 
 
Discussion 
The most recent statistics show a 12.84% estimated incidence of developing a 
psychiatric diagnosis for the first time after COVID-19 diagnosis (Taquet et al., 2021). 
That study had a sample size of 236,379 patients (Taquet et al., 2021). This quality 
improvement project found 6% of veterans with symptoms of mental illness in sample 
size of 50. This number may be lower than expected because the project population has 
an overall higher incidence of mental illness. Additionally, the veterans that screened 
positive were all greater than 100 days since their COVID-19 diagnosis; this may be 
useful for further use. Although in place, no one screened needed an immediate referral to 
the mental health clinic. 
 
 
Making phone contact with veterans was easier than anticipated. The use of the 
Doximity smart phone application may have increased the likelihood that the phone was 
answered; the caller ID showed the project site. Thirty-three veterans (66%) answered the 
phone on the first attempt. Eleven veterans answered the phone on the second attempt 
and six answered on the third attempt.  
Many veterans screened during this project expressed gratitude for the contact and 
screening. Several veterans shared how appreciative they were for the phone call, and 
how they felt valued by the medical center. One veteran further elaborated that this 
screening may present an opportunity for veterans to speak more candidly about their 
mental health in the setting of COVID-19 versus their military experience. The six 
veterans that declined to participate indicated there was nothing wrong with their mental 
health and did not feel the need to participate.  
 Limitations of this project include a small, mostly male sample size. Screening for 
depression, anxiety, psychosis, PTSD, and dementia was also time intensive. Initially, 
this project sought to identify veterans experiencing depression and anxiety. During the 
literature review, an increased incidence of psychosis, PTSD, and neurocognitive 
symptoms was also identified. This evidence suggested further screening may be 
beneficial, and the PCCL, PCL-5, and TMMS were included in the screening questions. 
The addition of these screening tools increased the length of time for screening. While 
time intensive, it was important to include these tools for this small, more vulnerable 
population. In analyzing the data, it was observed that no one screened positive for 
psychosis, PTSD, or dementia without having a positive screen for depression or anxiety.  
 
 
It is beyond the scope of this quality improvement project to determine if the 59% 
of COVID-19 positive veterans with an established history of mental illness have 
experienced an exacerbation of symptoms since their diagnosis. This does demonstrate 
the importance of screening this vulnerable population for mental illness since veterans 
have higher baseline of mental illness than the general population.  
Recommendations 
If beneficial for veterans and the mental health clinic, as determined by the mental 
health clinic leadership team, a policy or practice guideline for screening in veterans 
positive for COVID-19 with no previous mental illness will be established for continued 
use. Based upon the results of this project, it is recommended that initial screening of 
veterans utilizing the PHQ-9 and GAD-7 for depression and anxiety. Screening for 
psychosis, PTSD, and dementia would only occur if the veteran screened positive for 
depression or anxiety. It was also noted that the veterans who did screen positive did so 
100 days or more after their COVID-19 diagnosis; this may be a useful number to flag 
patient’s charts for screening. This is also consistent with data found in the literature 
review. This specific screening after COVID-19 diagnosis may also identify veterans 
with symptoms who may not have verbalized them before. Given the incidence of mental 
illness after COVID-19 diagnosis, it may be prudent to screen the veterans that were not 
included in this quality improvement project.  The veterans included in this project did 
not have a history of mental illness; screening did not occur with the veterans with an 
established history of mental illness for exacerbation.  Additional studies may be 





This quality improvement project highlights the importance of screening the 
veteran population for mental illness after a diagnosis of COVID-19. There was an 
increase in the number of COVID-19 cases from 300 to over 1,500 in a little over six 
months. This shows the importance of screening veterans efficiently after their COVID-
19 diagnosis. The project site currently has a process in place to contact veterans after 
COVID-19 diagnosis to assess their physical health; adding the PHQ-9 and GAD-7 to 
this phone call would be beneficial. Military veterans do have a higher incidence of 
mental illness; continued screening after COVID-19 diagnosis could continue to identify 
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Thombs, B. (2019). Accuracy 
of Patient Health 
Questionnaire-9 (PHQ-9) for 
screening to detect major 
depression: individual 
participant data meta-analysis. 
British Medical Journal, 365. 
https://dx.doi.org/10.1136/bmj.l
1476  
To determine the accuracy 
of the PHQ-9 for screening 
major depression. 
72 eligible studies were 
identified with a patient n 





PsycINFO, and Web 
of Science 
A cut-off score of 10 or above 
maximized combined 
sensitivity and specificity.  
Manea, L., Gilbody, S., & 
McMillan, D. (2015). A 
diagnostic meta-analysis of the 
Patient Health Questionnaire-9 
(PHQ-9) algorithm scoring 
method as a screen for 
depression. General Hospital 
Psychiatry, 37, 67- 75. 
https://dx.doi.org/10.1016/j.gen
hosppsych.2014.09.009  
The depression module of 
the PHQ-9 is a widely used 
depression screening 
instrument in the 
nonpsychiatric setting. This 
study summarizes the 
diagnostic accuracy of the 
PHQ-9. 
27 validation studies were 
found that validated the 
algorithm scoring method 
of the PHQ-9 in various 
settings. 
A systemic review of 
diagnostic accuracy 
studies of the PHQ-9 
using the algorithm 




to calculate summary 
sensitivity, specificity, 
likelihood ratios and 
diagnostic odds ratios 
for diagnosing MDD 
of the PHQ-9 were 
completed.  
If the scale is utilized using the 
algorithm method, there is a 
low sensitivity of predicting 
MDD. The standard cut-off 
point of > 10 of the summed-
item scoring method had a 
better sensitivity (0.77) and 
maintained good specificity 
(0.85).  
Limitations include study 
selection and data extraction 
was performed by one author.  
Newkirk, L., Kim, J., 
Thompson, J., Tinklenberg, J., 
Yesavage, J., & Taylor, J. 
(2004). Validation of a 26-point 
telephone version of the mini-
mental state examination. 
Journal of Geriatric Psychiatry 
and Neurology, 17(2). 81- 87. 
https://dx.doi.org/10.1177/0891
988704264534  
The objective of this study 
was to assess the convergent 
validity of a 26-point 
Telephone Mini-Mental 
State Examination 
(MMSE) in a.  
Hearing impairment 





Longitudinal cohort of 46 
Alzheimer’s disease (AD) 
patients 
Paired in-person and 
telephone MMSE 
observations were 
collected within 35 
days of each other. 
The 30-point Folstein 
MMSE was 
administered in-
person, and a 26-point 
telephone version of 
the MMSE.  
 
The Telephone MMSE can be 
used to validly estimate in-
person MMSE scores of 
patients with AD. Use of this 
practical measure can enhance 
reassessment if returning to the 
clinic is difficult or if a change 
in the patient’s medical 
condition merits a check of 
mental status by telephone. 
Total scoresfor the in-person 
and telephone MMSE versions 
 
 
correlated strongly (Pearson’s r 
= .88, P < .001). 
Plummer, F., Manea, L., 
Trepel, D., & McMillan, D. 
(2016). Screening for anxiety 
disorders with the GAD-7 and 
GGeAD-2: a systemic review 
and diagnostic metanalysis. 
General Hospital Psychiatry, 
39, 24- 31. 
https://dx.doi.org/10.1016/j.gen
hosppsych.2015.11.005  
To systemically review the 
accuracy of the GAD-7 and 
GAD-2 questionnaires for 
identifying anxiety disorders 
A total of 12 samples 
were identified involving 
5223 participants, aged 16 
or older in any setting 




and the Cochrane 
Library  
At the cutoff score of 10, the 
pooled estimate of sensitivity in 
the current review is 0.74. If 
using the GAD-7, clinicians 
may wish to consider cutoff 
points of 8 or 9, which appear 
to have increased sensitivity.  
Limitations include that two 
independent researchers were 
not used to select studies and 
extract data. Bias could also be 
found in the selective reporting 
of cutoff points on the scale.  
Tariq, S., Tumosa, N., Chibnall, 
J., Perry III, M., & Morley, J. 
(2006). Comparison of the St. 
Louis University mental status 
examination and the mini-
mental state examination for 
detecting dementia and mild 
neurocognitive disorder- a pilot 
study. American Journal of 
Geriatric Psychiatry, 14(11). 
900- 910.  
The objective of this study 
was to compare SLUMS 
and the MMSE for detecting 
dementia and mild 
neurocognitive 
disorder (MNCD) using 
Diagnostic and Statistical 
Manual of Mental 
Disorders, 
Fourth Edition (DSM–IV) 
criteria 
702 veterans at the VA 
Geriatric Research, 
Education, and Clinical 
Center in St. Louis, MO 
with normal cognitive 
functioning, MNCD, or 





These results suggest that the 
SLUMS and MMSE have 
comparable sensitivities, 
specificities, and area under the 
curve in detecting dementia 
Wortman, J., Jordan, A., 
Resick, P, Foa, E., Yarvis, J., 
Mintz, J., Litz, B., Weathers, 
F., Dondanville, K., Hall-Clark, 
B., Young-McCaughan, 
Hembree, E., & Peterson, A. 
(2016). Psychometric analysis 
of the PTSD checklist-5 (PCL-
5) among treatment-seeking 
military service members. 
Psychological Assessment, 
Evaluate the effectives of 
the PCL-5 with the new 
diagnostic criteria for PTSD 
from the DSM-5 
912 veterans in Fort 
Hood, TX 
Descriptive statistics 
to evaluate convergent 
relationships 
The PCL-5 was found to be 
psychometrically with a high 
internal consistency.  
Limitations of this study 
include that order effects of the 
presentation of the PCL 
versions could not be evaluated.  
 
 











ICD-9 and ICD-10 Codes for Exclusion Criteria 
Diagnosis ICD-9 ICD-10 
Major depressive disorder 296.2 F33 
Generalized anxiety disorder 300.02 F41.1 
Panic disorder 300.01 F41.0 
Obsessive-compulsive disorder 300.3 F42.9 
Adjustment disorder 309 F43.20 
Post-traumatic stress disorder 309.81 F43.10 
Schizophrenia 295.0 F20.9 
Unspecified psychosis 298.9 F29 
Bipolar I disorder 296.0 F31 
Bipolar II disorder 296.8 F31.81 
Suicide attempts 950.9 Z91.5 
Schizoaffective disorder 295.7 F25.9 







Screening Tool for Mental Illness after COVID-19 Diagnosis 
Identification Code:    Age/Gender:    Date of Diagnosis: 
 
Over the last 2 weeks: 












Little interest or pleasure in doing things PHQ-
9 
0 1 2 3  
Feeling down, depressed or hopeless 0 1 2 3  
Trouble falling asleep, staying asleep, or 
sleeping too much 
0 1 2 3  
Feeling tired or have little energy 0 1 2 3  
Poor appetite or overeating 0 1 2 3  
Feeling bad about yourself 0 1 2 3  
Trouble concentrating on things 0 1 2 3  
Moving or speaking too slowly, or the opposite, 
being fidgety or restless 
0 1 2 3  
Thoughts that you would be better off dead 0 1 2 3  
Column Totals      
Added Totals   
If you checked off any problems, how difficult 
have these problems made it for you to do your 
work, take care of things at home, or get along 
















       
Feeling nervous, anxious, or on edge GAD-
7 
0 1 2 3  
Not being able to stop or control worrying 0 1 2 3  
Worrying too much about different things 0 1 2 3  
Trouble relaxing 0 1 2 3  
Being so restless that it’s hard to sit still 0 1 2 3  
Becoming easily annoyed or irritable 0 1 2 3  
Feeling of afraid as if something awful might 
happen 
0 1 2 3  
Column Totals      
Added Totals   
If you checked off any problems, how difficult 
have these problems made it for you to do your 
work, take care of things at home, or get along 
















  Yes No  
Spending more time alone PCCL 1  
Arguing with family or friends 1  
The family is concerned 1  
Excess use of alcohol 1  
Use of street drugs (including cannabis) 1  
Sleep difficulties  2  
Poor appetite 2  
Depressive mood 2  
Poor concentration 2  
Restlessness 2  
Tension and nervousness 2  
Less pleasure from things 2  
Feeling people are watching you 3  
 
 
Feeling or hearing things that others cannot 3  
Ideas of reference 5  
Odd beliefs 5  
Odd manner of talking or speech 5  
Inappropriate affect 5  
Odd behavior or appearance 5  
First-degree family history of psychosis plus 
increased stress or deterioration of functioning  
5  
Total Score      
 









Repeated, disturbing, and unwanted memories of 
the 
stressful experience? 
PCL-5 0 1 2 3 4 
Repeated, disturbing dreams of the stressful 
experience? 
0 1 2 3 4 
Suddenly feeling or acting as if the stressful 
experience were actually happening again (as if 
you were actually back there 
reliving it)? 
0 1 2 3 4 
Feeling very upset when something reminded 
you of the 
stressful experience? 
0 1 2 3 4 
Having strong physical reactions when 
something reminded 
you of the stressful experience (for example, 
heart 
pounding, trouble breathing, sweating)? 
0 1 2 3 4 
Avoiding memories, thoughts, or feelings related 
to the 
stressful experience? 
0 1 2 3 4 
Avoiding external reminders of the stressful 
experience (for 
example, people, places, conversations, 
activities, objects, or 
situations)? 
0 1 2 3 4 
Trouble remembering important parts of the 
stressful 
experience? 
0 1 2 3 4 
Having strong negative beliefs about yourself, 
other people, 
or the world (for example, having thoughts such 
as: I am 
bad, there is something seriously wrong with me, 
no one can be trusted; the world is completely 
dangerous)? 
0 1 2 3 4 
Blaming yourself or someone else for the 
stressful 
experience or what happened after it? 
0 1 2 3 4 
Having strong negative feelings such as fear, 
horror, anger, 
guilt, or shame? 
0 1 2 3 4 
Loss of interest in activities that you used to 
enjoy? 
0 1 2 3 4 
Feeling distant or cut off from other people? 0 1 2 3 4 
Trouble experiencing positive feelings (for 
example, being 
unable to feel happiness or have loving feelings 
for people 
0 1 2 3 4 
 
 
close to you)? 
Irritable behavior, angry outbursts, or acting 
aggressively? 
0 1 2 3 4 
Taking too many risks or doing things that could 
cause you 
harm? 
0 1 2 3 4 
Being “super alert” or watchful or on guard? 0 1 2 3 4 
Feeling jumpy or easily startled? 0 1 2 3 4 
Having difficulty concentrating? 0 1 2 3 4 
Trouble falling or staying asleep? 0 1 2 3 4 







“What is the year? Season? Date? Day of the 
week? Month?” 
TMMSE  5 
“Where are we now: State? County? Town/city? 
Hospital? Floor?” 
 5 
The examiner names three unrelated objects 
clearly and slowly, then asks the patient to name 
all three of them. The patient’s response issued 
for scoring. The examiner repeats them until 
patient learns all of them, if possible.  
Number of trials: ___________ 
 3 
“I would like you to count backward from 100 
by sevens.” (93, 86, 79,72, 65, …) Stop after five 
answers. 
Alternative: “Spell WORLD backwards.” (D-L-
R-O-W) 
 5 
“Earlier I told you the names of three things. Can 
you tell me what those were?” 
 3 
“Repeat the phrase: ‘No ifs, ands, or buts.’”  1 
“Make up and write a sentence about anything.” 
(This sentence must contain a noun and a verb.) 
 1 









 Yes No 
Veteran agreeable to mental health referral   
Appropriate for Jefferson Barracks   
Need to be seen at John Cochran   
Preference for community setting   





























       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       






Informed Consent Verbal Script 
You are invited to participate in a research study conducted by Brittania Phillips and 
Anne Thatcher. The purpose of this research is identify veterans who may be at risk for 
mental illness and refer them to the appropriate care. 
You are consenting to participate in a quality improvement project about the development 
of mental illness symptoms after COVID-19 diagnosis. There is evidence that suggest 
that people without a history of mental illness are developing symptoms of mental illness 
after contracting COVID-19, including symptoms of depression, anxiety, PTSD, and 
psychosis. Your participation in this voluntary. If you choose, you will be screened for 
depression, anxiety, PTSD, psychosis, and neurocognitive disorders. If these symptoms 
are present, then you will receive a referral to the mental health clinic at the VA or a 
communicatory resource. Reasonable, foreseeable risks or discomforts may include the 
sensitivity of questions asked. Reasonable, expected benefits include accessing 
appropriate care for the symptoms you may be experiencing. 
Your participation will involve answering verbal questions using standardized assessment 
tools over the phone. This will take approximately 15 minutes. You were identified to be 
included based upon your COVID-19 diagnosis and past medical history. 
Approximately 100 veterans may be involved in this research at the St. Louis VA.  
There are no known risks associated with this research (other than the potential for mild 
boredom or fatigue). The possible benefits to you from this research are accessing mental 
health care for symptoms you are experiencing.  
Your participation is voluntary and you may choose not to participate in this study or 
withdraw your consent at any time. You will NOT be penalized in any way should you 
choose not to participate or withdraw.  
We will do everything we can to protect your privacy. As part of this effort, your identity 
will not be revealed in any publication that may result from this study. In rare instances, a 
researcher's study must undergo an audit or program evaluation by an oversight agency 
(such as the Office for Human Research Protection) that would lead to disclosure of your 
data as well as any other information collected by the researcher.  
Federal agencies such as the Office for Human Research Protection (OHRP), the 
Government Accounting Office (GAO), Office of Research Oversight (ORO), St. Louis 
VAHCS Institutional Review Board, VA Audit Committees and accrediting agencies will 
have access to the records and records are subject to audit or inspection by a funding 
agency or sponsor. A copy of this consent form will be filed in your medical records, and 
for your safety, your medical records may be flagged to alert other healthcare providers 
that you are participating in the study. Your medical records will include a note that you 




As a VA study participant, the VA (not you or your insurance) will provide necessary 
medical treatment should you be injured by being in this study. You will be treated for 
the injury at no cost to you. This care may be provided by the VASTLHCS or 
arrangements may be made for contracted care at another facility. You have not released 
this institution from liability for negligence. In case of research related injury resulting 
from this study, you should contact your study team. If you have questions about 
compensation and medical treatment for any study related injuries, you can call the 
Research & Education Service at VSATLHCS at 314-289-6333 
If you have any questions or concerns regarding this study, or if any problems arise, you 
may call the Investigator, Brittania Phillips or the Faculty Advisor, Anne Thatcher at 
(314) 652-4100 x64656. You may also ask questions or state concerns regarding your 
rights as a research participant to the Office of Research at the University of Missouri- St. 








Hello, this is [insert name], calling from the St. Louis VA John Cochran. I was calling to 
see how your health has been, and to ask you a few follow up questions. I will attempt to 
call you again on [specific date] or you may reach me at (314) 652-4100 x 53313. If I do 





Note Template for CPRS (EMR) 
Veteran Name 
The above veteran was screened for symptoms of mental illness using the PHQ-9, GAD-
7, PCL-5, PCCL, and MMSE. This screening was conducted as part of a quality 
improvement project through the mental health services.  
PHQ-9 
Little interest or pleasure in doing things: 
Feeling down, depressed or hopeless: 
Trouble falling asleep, staying asleep, or sleeping too much: 
Feeling tired or have little energy: 
Poor appetite or overeating: 
Feeling bad about yourself: 
Trouble concentrating on things: 
Moving or speaking too slowly, or the opposite, being fidgety or restless: 
Thoughts that you would be better off dead: 
If you checked off any problems, how difficult have these problems made it for 




 Feeling nervous, anxious, or on edge: 
Not being able to stop or control worrying: 
Worrying too much about different things: 
Trouble relaxing: 
Being so restless that it’s hard to sit still: 
Becoming easily annoyed or irritable: 
Feeling of afraid as if something awful might happen: 
If you checked off any problems, how difficult have these problems made it for 






 Repeated, disturbing, and unwanted memories of the stressful experience:  
Repeated, disturbing dreams of the stressful experience:  
Suddenly feeling or acting as if the stressful experience were actually happening 
again (as if you were actually back there reliving it):  
Feeling very upset when something reminded you of the stressful experience:  
Having strong physical reactions when something reminded you of the stressful 
experience (for example, heart pounding, trouble breathing, sweating):  
Avoiding memories, thoughts, or feelings related to the stressful experience:  
Avoiding external reminders of the stressful experience (for example, people, 
places, conversations, activities, objects, or situations):  
Trouble remembering important parts of the stressful experience:  
Having strong negative beliefs about yourself, other people, or the world (for 
example, having thoughts such as: I am bad, there is something seriously wrong 
with me, no one can be trusted; the world is completely dangerous):  
Blaming yourself or someone else for the stressful experience or what happened 
after it:  
Having strong negative feelings such as fear, horror, anger, guilt, or shame:  
Loss of interest in activities that you used to enjoy:  
Feeling distant or cut off from other people:  
Trouble experiencing positive feelings (for example, being unable to feel 
happiness or have loving feelings for people close to you):  
Irritable behavior, angry outbursts, or acting aggressively:  
Taking too many risks or doing things that could cause you harm:  
Being “super alert” or watchful or on guard:  
Feeling jumpy or easily startled:  
Having difficulty concentrating: 






Spending more time alone: 
Arguing with family or friends: 
The family is concerned: 
Excess use of alcohol: 
Use of street drugs (including cannabis): 





Tension and nervousness: 
Less pleasure from things: 
Feeling people are watching you: 
Feeling or hearing things that others cannot: 
Ideas of reference: 
Odd beliefs: 
Odd manner of talking or speech: 
Inappropriate affect: 
Odd behavior or appearance: 





“What is the year? Season? Date? Day of the week? Month?” 
“Where are we now: State? County? Town/city? Hospital? Floor?” 
 
 
The examiner names three unrelated objects clearly and slowly, then asks the 
patient to name all three of them. The patient’s response issued for scoring. The 
examiner repeats them until patient learns all of them, if possible.  
Number of trials: ___________ 
“I would like you to count backward from 100 by sevens.” (93, 86, 79,72, 65, …) 
Stop after five answers. 
Alternative: “Spell WORLD backwards.” (D-L-R-O-W) 
“Earlier I told you the names of three things. Can you tell me what those were?” 
“Repeat the phrase: ‘No ifs, ands, or buts.’” 
“Make up and write a sentence about anything.” (This sentence must contain a 
noun and a verb.) 
MMSE results:  
 
The veteran was/was not amenable to a mental health clinic referral. A consult has been 
placed if appropriate. The veteran has been supplied with the number for the crisis line 
and resources provided.
 
 
 
